CONCORDBIONSEMay 30, 2025

Concord Biotech Limited

3,745words
1turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
bol: CONCORDBIO To General Manager, Lis(cid:31)ng Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960 Dear Sir/Ma’am, Sub.: Investor’s Presenta(ci
18%
25 Consolidated Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +18% 1,200.1 1,016.9 +17% 506.3 431.5 +21% 371.6 308.1 +35% 319.0 429.9 +42% 190.4 134.3
17%
l Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +18% 1,200.1 1,016.9 +17% 506.3 431.5 +21% 371.6 308.1 +35% 319.0 429.9 +42% 190.4 134.3 +48% 140.4 95.0 Q4FY2
21%
e (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +18% 1,200.1 1,016.9 +17% 506.3 431.5 +21% 371.6 308.1 +35% 319.0 429.9 +42% 190.4 134.3 +48% 140.4 95.0 Q4FY24 Q4FY25 FY24 FY2
35%
DA (Rs. in Crs) PAT (Rs. in Crs) +18% 1,200.1 1,016.9 +17% 506.3 431.5 +21% 371.6 308.1 +35% 319.0 429.9 +42% 190.4 134.3 +48% 140.4 95.0 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25 F
42%
(Rs. in Crs) +18% 1,200.1 1,016.9 +17% 506.3 431.5 +21% 371.6 308.1 +35% 319.0 429.9 +42% 190.4 134.3 +48% 140.4 95.0 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q
48%
1,200.1 1,016.9 +17% 506.3 431.5 +21% 371.6 308.1 +35% 319.0 429.9 +42% 190.4 134.3 +48% 140.4 95.0 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25 FY24 FY25 G
200 bps
Y24 FY25 Q4FY24 Q4FY25 FY24 FY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -200 bps 72.1% 70.1% -290 bps 77.5% 74.5% +220 bps -25 bps +290 bps +70 bps 42.1% 44.3% 42.4% 4
72.1%
Q4FY24 Q4FY25 FY24 FY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -200 bps 72.1% 70.1% -290 bps 77.5% 74.5% +220 bps -25 bps +290 bps +70 bps 42.1% 44.3% 42.4% 42.2% 2
70.1%
4 Q4FY25 FY24 FY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -200 bps 72.1% 70.1% -290 bps 77.5% 74.5% +220 bps -25 bps +290 bps +70 bps 42.1% 44.3% 42.4% 42.2% 29.8% 3
290 bps
5 FY24 FY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -200 bps 72.1% 70.1% -290 bps 77.5% 74.5% +220 bps -25 bps +290 bps +70 bps 42.1% 44.3% 42.4% 42.2% 29.8% 32.7% 30.3
77.5%
FY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -200 bps 72.1% 70.1% -290 bps 77.5% 74.5% +220 bps -25 bps +290 bps +70 bps 42.1% 44.3% 42.4% 42.2% 29.8% 32.7% 30.3% 31.0
Speaking time
Investor Relations Advisor
1
Advertisement
Opening remarks
Investor Relations Advisor
Concord Biotech Limited CIN: L24230GJ1984PLC007440 Mr. Lalit Sethi – Chief Financial Officer lalitsethi@concordbiotech.com www.concordbiotech.com Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Sagar Shroff / Mr. Vatsal Shah sagar.shroff@sgapl.net / vatsal.shah@sgapl.net +91 98205 19303 / +91 88796 59884 www.sgapl.net
Advertisement
← All transcriptsCONCORDBIO stock page →